Skip to main content

Table 3 Adjusted odds ratios (95% confidence intervals) of NAFLD according to BMI and HOMA-IR status and serum SHBG quartiles using adjusted logistic regression

From: Association of sex hormone-binding globulin with nonalcoholic fatty liver disease in Chinese adults

  SHBG (nmol/L) p for trend
Quartile 1 Quartile 2 Quartile 3 Quartile 4
BMI < 24 kg/m2
(N = 1696)
<  45.03 45.03–60.90 60.91–80.98 >  80.98  
 Model 1 1.00 0.50 (0.38–0.66) 0.23 (0.17–0.31) 0.15 (0.11–0.21) <  0.001
 Model 2 1.00 0.56 (0.42–0.75) 0.29 (0.21–0.40) 0.24 (0.17–0.34) <  0.001
 Model 3 1.00 0.60 (0.46–0.84) 0.35 (0.25–0.48) 0.31 (0.21–0.45) <  0.001
BMI ≥ 24 kg/m2
(N = 1216)
<  32.70 32.70–43.10 43.11–56.30 >  56.30  
 Model 1 1.00 0.53 (0.34–0.83) 0.33 (0.21–0.51) 0.17 (0.11–0.27) <  0.001
 Model 2 1.00 0.57 (0.36–0.89) 0.37 (0.24–0.57) 0.21 (0.14–0.32) <  0.001
 Model 3 1.00 0.70 (0.44–1.12) 0.49 (0.30–0.78) 0.31 (0.19–0.51) <  0.001
p for interaction 0.150
HOMA-IR < 2
(N = 1780)
<  45.20 45.20–60.10 60.11–79.38 >  79.38  
 Model 1 1.00 0.55 (0.42–0.72) 0.29 (0.22–0.39) 0.17 (0.13–0.23) <  0.001
 Model 2 1.00 0.64 (0.49–0.85) 0.40 (0.29–0.54) 0.32 (0.23–0.44) <  0.001
 Model 3 1.00 0.67 (0.50–0.89) 0.43 (0.31–0.59) 0.34 (0.24–0.49) <  0.001
HOMA-IR ≥ 2
(N = 1132)
<  31.50 31.50–41.60 41.61–55.68 >  55.68  
 Model 1 1.00 0.76 (0.47–1.21) 0.41 (0.27–0.64) 0.16 (0.10–0.25) <  0.001
 Model 2 1.00 0.84 (0.52–1.36) 0.46 (0.29–0.73) 0.21 (0.14–0.33) <  0.001
 Model 3 1.00 0.83 (0.50–1.36) 0.43 (0.27–0.70) 0.22 (0.13–0.36) <  0.001
p for interaction 0.021
  1. Model 1: Adjusted for age, sex and household income
  2. Model 2: Adjusted for the variables in Model 1 plus WHR, trunk fat, current smoking and drinking, physical activity (MET), hypertension and diabetes
  3. Model 3: Adjusted for the variables in Model 2 plus serum glucose, insulin resistance (HOMA-IR), TG, HDL-C, ALT, UA, testosterone and DHEAS levels
  4. NAFLD nonalcoholic fatty liver disease; SHBG sex hormone-binding globulin; BMI body mass index; HOMA-IR homeostasis model assessment of insulin resistance